Last reviewed · How we verify
Gasmotin
Gasmotin is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently in Phase 3 development.
Gasmotin, also known as mosapride citrate, is a medication that has been studied in clinical trials for various conditions, including gastritis, functional dyspepsia, type 2 diabetes, functional constipation, and healthy individuals. The medication has been tested in two different formulations, GR107719B (Formulation 1 and Formulation 2), in comparison to a reference formulation of mosapride citrate.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Gasmotin |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Target | Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Two Prokinetics in Patients With Functional Dyspepsia (NA)
- The Comparative Analysis Between Motilitone and Gasmotin for the Symptom Relief in Gallstone Patients With Functional Dyspepsia (NA)
- Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PHASE3)
- Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2) (PHASE3)
- The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones (PHASE4)
- Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia (PHASE3)
- A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions (PHASE1)
- Effect of Proton Pump Inhibitor and Mosapride on Acid Pocket in Gastroesophageal Reflux Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gasmotin CI brief — competitive landscape report
- Gasmotin updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI
Frequently asked questions about Gasmotin
What is Gasmotin?
Who makes Gasmotin?
What development phase is Gasmotin in?
What does Gasmotin target?
Related
- Target: All drugs targeting Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9
- Manufacturer: Daewoong Pharmaceutical Co. LTD. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing